伪-HYDROXYLINOLEICACID | 57818-44-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 伪-HYDROXYLINOLEICACID
• 英文名称: alpha-Hydroxylinoleic acid
• 英文别名: (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid
• CAS: 57818-44-7
• 化学式: C₁₈H₃₂O₃
• 分子量: 296.4
• InChiKey: AFDSETGKYZMEEA-HZJYTTRNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  21
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Anticancer agents, perfumes or foods and drinks containing omega-hydroxyfatty acids
  申请人：——

  公开号：US20030055105A1

  公开（公告）日：2003-03-20

  The present invention relates to drugs and, particularly, to anticancer agents. More particularly, the present invention relates to an anticancer agents containing, as an active ingredient, at least one compound selected from the group consisting of &ohgr;-hydroxy fatty acids and salts or esters thereof, hydroxy oxo-fatty acids and salts or esters thereof, lactones, macrocyclic ketones, and macrocyclic diesters having specific chemical structures. With respect to the compounds described above used in the present invention, since the activities of killing cancer and inhibiting cancer metastasis are significantly high, the effects of preventing the recurrence of cancer and preventing cancer are exhibited, the cytotoxicity is significantly low, and a small dose is effective, it is possible to provide anticancer agents having significantly decreased side effects. Additionally, use in combination with known antitumor agents can further enhance the activity of inhibiting cancer metastasis. Among the anticancer agents of the present invention, &ohgr;-hydroxy fatty acids can be easily obtained in high purities by hydrolyzing lactones which are also the anticancer agents of the present invention.

  本发明涉及药物，特别是抗癌剂。更具体地说，本发明涉及一种抗癌剂，其含有至少一种从以下化合物组合中选择的活性成分，包括ω-羟基脂肪酸及其盐或酯、羟基酮脂肪酸及其盐或酯、内酯、大环酮和具有特定化学结构的大环二酯。对于本发明中所述的上述化合物，由于其杀灭癌细胞和抑制癌转移的活性显著高，具有预防癌症复发和预防癌症的效果，细胞毒性显著低，且小剂量就能发挥作用，因此能够提供具有显著降低副作用的抗癌剂。此外，与已知的抗肿瘤药物结合使用可以进一步增强抑制癌转移的活性。在本发明的抗癌剂中，ω-羟基脂肪酸可以通过水解也是本发明的抗癌剂的内酯轻松获得高纯度。
• Treatment of tumours
  申请人：Hagstrom Tomas

  公开号：US20050192262A1

  公开（公告）日：2005-09-01

  The present invention refers to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are -5-androstene-17-ol, androstane-17-ol-pregnane-17-ol or pregnane-17-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3β,17-diol or androstane-3β-diol, an enzyme and a sulfotransferase to provide 5-androstene-17-ol-3β-sulfate or corresponding andros tane derivative (17-AEDS or 17-AADS); and mixing the 17-AEDS or 17-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to peroxisome proliferators-activated receptor-(PPAR) is produced.

  本发明涉及类固醇衍生物作为药物的使用。更具体地说，本发明还涉及在制造用于治疗良性和/或恶性肿瘤的药物中使用5-雄烯-、5-孕酮或相应饱和衍生物（雄烷-或孕烷-）的类固醇衍生物，该药物能够中断Wnt信号传导中的干扰，例如在G1期细胞周期停滞，并/或提供抗血管生成效应。此类类固醇衍生物的例子包括-5-雄烯-17-醇、雄烷-17-醇-孕烷-17-醇或孕烷-17-醇衍生物。在另一方面，本发明还涉及一种制造用于治疗良性和/或恶性肿瘤和/或炎症状态的药物的方法，包括以下步骤：将5-雄烷-3β,17-二醇或雄烷-3β-二醇、酶和硫酸转移酶接触，以提供5-雄烯-17-醇-3β-硫酸酯或相应的雄烷衍生物（17-AEDS或17-AADS）；并将所生产的17-AEDS或17-AADS与适当的载体混合；从而产生能够作为过氧化物酶体增殖物激活受体-（PPAR）配体的药物。
• TREATMENT OF TUMOURS
  申请人：Hagstrom Tomas

  公开号：US20070111973A1

  公开（公告）日：2007-05-17

  The present invention refers to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wut-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are -5-androstene-17-ol, androstane-17-ol-pregnane-17-ol or pregnane-17-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3B,17-dio 1 or androstane-3B-diol, an enzyme and a sulfotransferase to provide 5-androstene-17-ol-3B-sulfate or corresponding andros tane derivative (17-AEDS or 17-AADS); and mixing the 17-AEDS or 17-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to peroxisome proliferators-activated receptor—(PPAR) is produced.

  本发明涉及类固醇衍生物用作药物。更具体地，本发明还涉及在制造用于治疗良性和/或恶性肿瘤的药物中使用5-雄烯烷，5-孕酮或相应饱和衍生物（雄烷或孕烷）的类固醇衍生物，该药物能够中断Wut信号传导的紊乱，例如在G1期细胞周期停滞，并/或提供血管生成抑制作用。此类类固醇衍生物的例子是-5-雄烯烷-17-醇，雄烷-17-醇-孕烷-17-醇或孕烷-17-醇衍生物。此外，本发明还涉及一种用于制备用于治疗良性和/或恶性肿瘤和/或炎症症状的药物的方法，包括以下步骤：接触5-雄烷-3B，17-二酮或雄烷-3B-二醇，一种酶和一种硫酸转移酶，以提供5-雄烯烷-17-醇-3B-硫酸酯或相应的雄烷衍生物（17-AEDS或17-AADS）;并将所生产的17-AEDS或17-AADS与适当的载体混合；从而制备出能够作为过氧化物酶体增殖物激活受体-（PPAR）配体的药物。
• ANTICANCER AGENTS, PERFUMES OR FOODS AND DRINKS CONTAINING $g(v)-HYDROXYFATTY ACIDS
  申请人：SODA AROMATIC COMPANY, LIMITED

  公开号：EP1249236A1

  公开（公告）日：2002-10-16

  The present invention relates to drugs and, particularly, to anticancer agents. More particularly, the present invention relates to an anticancer agents containing, as an active ingredient, at least one compound selected from the group consisting of ω-hydroxy fatty acids and salts or esters thereof, hydroxy oxo-fatty acids and salts or esters thereof, lactones, macrocyclic ketones, and macrocyclic diesters having specific chemical structures. With respect to the compounds described above used in the present invention, since the activities of killing cancer and inhibiting cancer metastasis are significantly high, the effects of preventing the recurrence of cancer and preventing cancer are exhibited, the cytotoxicity is significantly low, and a small dose is effective, it is possible to provide anticancer agents having significantly decreased side effects. Additionally, use in combination with known antitumor agents can further enhance the activity of inhibiting cancer metastasis. Among the anticancer agents of the present invention, ω-hydroxy fatty acids can be easily obtained in high purities by hydrolyzing lactones which are also the anticancer agents of the present invention.

  本发明涉及药物，特别是抗癌剂。 更具体地说，本发明涉及一种抗癌剂，其中含有至少一种选自具有特定化学结构的ω-羟基脂肪酸及其盐或酯、羟基氧代脂肪酸及其盐或酯、内酯、大环酮和大环二酯组成的组的化合物作为活性成分。 对于本发明中使用的上述化合物，由于杀灭癌症和抑制癌症转移的活性显著较高，具有防止癌症复发和预防癌症的效果，细胞毒性显著较低，且小剂量即可有效，因此可以提供副作用显著降低的抗癌剂。此外，与已知的抗肿瘤药物联合使用可进一步提高抑制癌症转移的活性。在本发明的抗癌剂中，ω-羟基脂肪酸很容易通过水解内酯得到高纯度的ω-羟基脂肪酸，这些内酯也是本发明的抗癌剂。
• Graft copolymer latices
  申请人：Cytec Surface Specialties S.A./N.V.

  公开号：EP2481763A1

  公开（公告）日：2012-08-01

  The invention relates to a graft copolymer latex comprising the which comprises a graft copolymer ABC of at least one olefinically unsaturated monomer C and at least one modified alkyd resin A2B or modified oil A1B which modified alkyd resin A2B or modified oil A1B have chain-pendant olefinically unsaturated groups, to a process for its preparation, and the use thereof a binder in coating compositions.

  本发明涉及一种接枝共聚物胶乳，它包括至少一种烯烃不饱和单体 C 和至少一种改性醇酸树脂 A2B 或改性油 A1B 的接枝共聚物 ABC（其中改性醇酸树脂 A2B 或改性油 A1B 具有链悬垂的烯烃不饱和基团），还涉及其制备工艺及其在涂料组合物中作为粘合剂的用途。